ATE365209T1 - Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie - Google Patents

Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie

Info

Publication number
ATE365209T1
ATE365209T1 AT93911198T AT93911198T ATE365209T1 AT E365209 T1 ATE365209 T1 AT E365209T1 AT 93911198 T AT93911198 T AT 93911198T AT 93911198 T AT93911198 T AT 93911198T AT E365209 T1 ATE365209 T1 AT E365209T1
Authority
AT
Austria
Prior art keywords
steroid hormone
methods
molecular switch
present
provides
Prior art date
Application number
AT93911198T
Other languages
English (en)
Inventor
Elisabetta Vegeto
Donald Mcdonnell
Bert O'malley
William Schrader
Ming-Jer Tsai
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/882,771 external-priority patent/US5364791A/en
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE365209T1 publication Critical patent/ATE365209T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8237—Externally regulated expression systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8237—Externally regulated expression systems
    • C12N15/8238—Externally regulated expression systems chemically inducible, e.g. tetracycline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93911198T 1992-05-14 1993-05-11 Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie ATE365209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/882,771 US5364791A (en) 1992-05-14 1992-05-14 Progesterone receptor having C. terminal hormone binding domain truncations
US93924692A 1992-09-02 1992-09-02

Publications (1)

Publication Number Publication Date
ATE365209T1 true ATE365209T1 (de) 2007-07-15

Family

ID=27128671

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911198T ATE365209T1 (de) 1992-05-14 1993-05-11 Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie

Country Status (8)

Country Link
US (3) US5935934A (de)
EP (1) EP0745121B1 (de)
JP (1) JPH07509694A (de)
AT (1) ATE365209T1 (de)
AU (1) AU685054C (de)
CA (1) CA2135644C (de)
DE (1) DE69334150T2 (de)
WO (1) WO1993023431A1 (de)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
ATE365209T1 (de) 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US6004941A (en) * 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
US5789156A (en) * 1993-06-14 1998-08-04 Basf Ag Tetracycline-regulated transcriptional inhibitors
US5866755A (en) * 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
ES2140359T1 (es) * 1993-06-14 2000-03-01 Basf Ag Control preciso de expresion genetica en celulas eucarioticas mediante promotores que responden a la tetaciclina.
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5589362A (en) * 1993-06-14 1996-12-31 Basf Aktiengesellschaft Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US5912411A (en) * 1993-06-14 1999-06-15 University Of Heidelberg Mice transgenic for a tetracycline-inducible transcriptional activator
US5888981A (en) 1993-06-14 1999-03-30 Basf Aktiengesellschaft Methods for regulating gene expression
US5654168A (en) * 1994-07-01 1997-08-05 Basf Aktiengesellschaft Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
US5859310A (en) 1993-06-14 1999-01-12 Basf Aktiengesellschaft Mice transgenic for a tetracycline-controlled transcriptional activator
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
WO1995018380A1 (en) * 1993-12-30 1995-07-06 The Salk Institute For Biological Studies Novel uses for gal4-receptor constructs
US5935849A (en) 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5840576A (en) * 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
EP0813604B1 (de) * 1995-03-03 2005-04-20 Syngenta Participations AG Kontrolle der pflanzengenexpression durch rezeptor-vermittelte transaktivation in gegenwart von einem chemischen ligand
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6495364B2 (en) * 1995-05-23 2002-12-17 Neurotech, S.A. Mx-1 conditionally immortalized cells
RU97121687A (ru) 1995-05-26 2005-01-20 Синджента Лимитед (Gb) Ген-переключатель, представляющий ген рецептора экдизона
WO1997010337A1 (en) * 1995-09-15 1997-03-20 Baylor College Of Medicine Steroid receptor coactivator compositions and methods of use
WO1997010813A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
HUP9900029A3 (en) * 1995-10-10 2001-02-28 Novartis Ag Juvenile hormone or one of its agonists as a chemical ligand to control gene expression in plants by receptor mediated transactivation
US6610828B1 (en) 1996-05-24 2003-08-26 Syngenta Limited Heliothis ecdysone receptor
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
EP0935657B1 (de) * 1996-10-29 2007-08-29 Baylor College Of Medicine Modifizierte steroid-hormon rezeptoren
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
AU4845297A (en) * 1997-06-20 1998-12-24 Case Western Reserve University Expression system for production of therapeutic proteins
EP0988388A2 (de) 1997-07-24 2000-03-29 Valentis Inc. Ghrh-expressionssystem und dessen verwendungsmethoden
WO1999047178A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Novel complementing receptor-ligand pairs and adoptive immunotherapy using same
CA2327400A1 (en) * 1998-04-06 1999-10-14 Bunsen Rush Laboratories, Inc. Directed evolution biosensors
JP2003520758A (ja) 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド 抗エストロゲン耐性乳癌のｒｘｒモジュレーターを用いた処置
JP2002525053A (ja) 1998-09-10 2002-08-13 パイオニア ハイ−ブレッド インターナショナル， インコーポレイテッド エクジソンレセプターおよびそれらの使用のための方法
CA2362970A1 (en) * 1999-02-19 2000-08-24 Octagene Gmbh Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
CA2367037A1 (en) * 1999-03-03 2000-09-08 Genelabs Technologies, Inc. Dna binding compound-mediated molecular switch system
US7189506B1 (en) 1999-03-03 2007-03-13 Genelabs Technologies, Inc. DNA binding compound-mediated molecular switch system
EP1181360A1 (de) * 1999-05-28 2002-02-27 Sangamo Biosciences Inc. Molekulare schalter
WO2001007919A1 (fr) * 1999-07-23 2001-02-01 Olympus Optical Co., Ltd. Procede visant a examiner une substance ayant une interaction avec un recepteur hormonal
CA2925551A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
DE19958159A1 (de) 1999-12-02 2001-06-07 Degussa Neue für das glk-Gen codierende Nukleotidsequenzen
ATE361934T1 (de) 1999-12-30 2007-06-15 Harvard College Verfahren zur modulierung der aktivität von th2- zellen durch modulierung der aktivität von xbp-1
PT1741445E (pt) 2000-01-21 2013-11-11 Novartis Ag Combinações incluindo inibidores de dipeptidilpeptidase-iv e agentes antidiabéticos
WO2001053479A2 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Molecular switches ii
US7132277B1 (en) 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
ES2374061T3 (es) 2000-03-13 2012-02-13 Engene, Inc. Composiciones y métodos para la expresión regulada de proteína en el intestino.
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US6750015B2 (en) * 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
US7011972B2 (en) * 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
EP1326969B1 (de) 2000-09-25 2009-04-15 Genetronics, Inc. Verbessertes system zur regulation der transgenexpression
CA2440367A1 (en) * 2000-10-20 2002-08-15 Canji, Inc. Aptamer-mediated regulation of gene expression
WO2002048195A2 (en) * 2000-10-23 2002-06-20 Engeneos, Inc. Engineered stimulus-responsive switches
WO2002061102A2 (en) 2000-10-24 2002-08-08 Syngenta Participations Ag Control of gene expression in plants
PL367162A1 (en) 2001-04-02 2005-02-21 Wyeth Pd-1, a receptor for b7-4, and uses therefor
ATE403676T1 (de) 2001-05-31 2008-08-15 Novartis Ag Neue östrogenrezeptorligandenbindungsdomänen varianten und neue liganden und pharmazeutische zusammensetzungen
US20020197670A1 (en) * 2001-06-22 2002-12-26 Price Thomas M. Membrane associated progesterone receptor
KR100460478B1 (ko) * 2001-08-13 2004-12-08 김경섭 신규한 ｄｎａ 결합 단백질 및 이를 이용한 유전자 발현시스템
WO2003038112A2 (en) 2001-10-26 2003-05-08 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
MXPA04005713A (es) * 2001-12-11 2005-06-06 Baylor College Medicine Complemento de la hormona de liberacion de la hormona de crecimiento para tratar sujetos cronicamente enfermos.
EP1388352A1 (de) 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
US20060019964A1 (en) * 2002-10-16 2006-01-26 Ancliff Ranchael A Compounds
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
ATE441417T1 (de) * 2002-12-20 2009-09-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
AU2003211903A1 (en) * 2003-01-29 2004-09-09 Toyo Boseki Kabushiki Kaisha Mutant receptor and process for producing the same, method of separately evalauting ligands with the use of mutant receptor and normal receptor, screening method and kit therefor.
WO2004085611A2 (en) * 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
PT1615909E (pt) * 2003-04-23 2008-10-30 Glaxo Group Ltd Derivados de piperazina e a sua utilização para o tratamento de doenças neurológicas e psiquiátricas
WO2005028630A2 (en) 2003-09-19 2005-03-31 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
WO2005113015A1 (en) * 2004-05-24 2005-12-01 Niklas Arnberg Enhanced gene delivery using viral vectors
WO2005123723A1 (en) * 2004-06-18 2005-12-29 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
WO2006017813A2 (en) * 2004-08-04 2006-02-16 University Of Utah Research Foundation Methods and compositions for detecting steroids
US20060040298A1 (en) * 2004-08-05 2006-02-23 Azriel Schmidt Rhesus monkey NURR1 nuclear receptor
DE602005011458D1 (de) 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
WO2006037215A1 (en) * 2004-10-04 2006-04-13 National Research Council Of Canada Expression system, components thereof and methods of use
US7935788B2 (en) * 2004-10-04 2011-05-03 National Research Council Of Canada Reverse cumate repressor mutant
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DK1920248T3 (da) 2005-04-05 2010-12-13 Allergan Inc Clostridialt-toksin-aktivitetsassays
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
TW200716749A (en) * 2005-05-19 2007-05-01 Schering Ag Interferon-beta gene therapy using an improved, regulated expression system
KR20080030956A (ko) * 2005-05-19 2008-04-07 바이엘 쉐링 파마 악티엔게젤샤프트 개선된 조절 발현 체계를 사용한 질병의 치료
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
HRP20140091T4 (hr) 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Davanje inhibitora dipeptidil peptidaze
JP5134540B2 (ja) 2005-09-19 2013-01-30 アラーガン、インコーポレイテッド クロストリジウム毒素活性化クロストリジウム毒素
PE20071068A1 (es) 2005-12-20 2007-12-13 Glaxo Group Ltd Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
AU2007285472B2 (en) * 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
EP3031825B1 (de) 2008-03-14 2019-07-24 Allergan, Inc. Immunbasierte aktivitätsassays von botulinum-toxin serotyp a
EP2348863A4 (de) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc Borhaltige kleine moleküle
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
EP3281953B1 (de) 2009-03-13 2019-10-02 Allergan, Inc. Immunobasierte neu ausgerichtete endopeptidaseaktivitätstests
KR20200146046A (ko) 2009-03-13 2020-12-31 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
KR20120107988A (ko) 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
KR101930962B1 (ko) 2010-01-25 2018-12-19 알러간, 인코포레이티드 단일-사슬 단백질의 그의 이-사슬 형태로의 세포내 전환 방법
JP5711270B2 (ja) 2010-02-03 2015-04-30 武田薬品工業株式会社 アポトーシスシグナル調節キナーゼ１阻害剤
EP2650003B1 (de) 2010-05-20 2016-07-27 Allergan, Inc. Abbaubare clostridientoxine
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
WO2012109238A2 (en) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Methods for increasing immune responses using agents that directly bind to and activate ire-1
PL3049473T3 (pl) 2013-09-25 2022-02-07 Engene, Inc. Podwójnie derywatyzowane nanocząstki chitozanu i sposoby ich wytwarzania i stosowania do transferu genów in vivo
ES2724300T3 (es) 2013-09-25 2019-09-10 Univ Cornell Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
RU2714157C2 (ru) 2015-02-06 2020-02-12 Хит Байолоджикс, Инк. Вектор, коэкспрессирующий молекулы для вакцинации и костимулирующие молекулы
SG10201913576RA (en) 2015-10-01 2020-02-27 Heat Biologics Inc Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
EP4249503A3 (de) 2017-02-27 2023-12-20 Shattuck Labs, Inc. Chimäre proteine auf vsig8-basis
CN112351991A (zh) 2017-12-20 2021-02-09 阿勒根公司 肉毒杆菌毒素细胞结合结构域多肽及其用于治疗纤维化相关障碍的方法
CA3109354A1 (en) 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
CN117813320A (zh) 2021-07-30 2024-04-02 Inserm(法国国家健康医学研究院) 嵌合蛋白和免疫治疗方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
EP0451206A4 (en) 1988-12-23 1992-07-22 The Salk Institute For Biological Studies Receptor transcription-repression activity compositions and methods
JPH04506073A (ja) * 1989-05-26 1992-10-22 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ ステロイド／サイロイドスーパーファミリーのレセプターの優性の負のメンバー
CA2034220A1 (en) * 1990-01-16 1991-07-17 Donald P. Mcdonnell Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vector
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0517895B1 (de) * 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5215916A (en) * 1991-06-19 1993-06-01 The United States Of America As Represented By The Department Of Health & Human Services Super glucocorticoid receptors: receptors with increased affinity and specificity for glucocorticoid steriods
WO1993006215A1 (en) * 1991-09-17 1993-04-01 The Salk Institute For Biological Studies Receptor of the thyroid/steroid hormone receptor superfamily
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
EP0632722A4 (de) * 1992-03-20 1997-07-30 Baylor College Medicine In form-imc-beschichtungsverfahren mit doppelaushaertung zur herstellung von abriebfesten,beschichteten,thermoplastischen gegenstaenden.
EP0577932A3 (de) * 1992-05-08 1995-04-19 American Cyanamid Co Entwicklung von einem "Screening" für den Nachweis von androgenen Rezeptorenagonisten und Antagonisten.
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US6416998B1 (en) 1992-09-02 2002-07-09 Baylor College Of Medicine Plasmid encoding a modified steroid hormone
JP3913309B2 (ja) * 1997-03-07 2007-05-09 Ｓｕｍｃｏ Ｔｅｃｈｘｉｖ株式会社 半導体単結晶製造方法および単結晶引上装置の整流筒の装着用治具

Also Published As

Publication number Publication date
JPH07509694A (ja) 1995-10-26
EP0745121B1 (de) 2007-06-20
US5935934A (en) 1999-08-10
DE69334150T2 (de) 2008-03-13
AU685054C (en) 2003-02-27
WO1993023431A1 (en) 1993-11-25
US5874534A (en) 1999-02-23
AU4241793A (en) 1993-12-13
EP0745121A4 (de) 1996-08-20
DE69334150D1 (de) 2007-08-02
CA2135644A1 (en) 1993-11-25
US6599698B1 (en) 2003-07-29
EP0745121A1 (de) 1996-12-04
AU685054B2 (en) 1998-01-15
CA2135644C (en) 2009-01-27

Similar Documents

Publication Publication Date Title
ATE365209T1 (de) Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
ATE371736T1 (de) Modifizierte steroid-hormon rezeptoren
ATE148166T1 (de) Elemente für retinsäureantwortzusammensetzung und nachweisverfahren
DK0673420T3 (da) Mammale receptorer for interleukin 10 (IL-10)
DK0714392T3 (da) Heterocykliske neurokinin-antagonister
ATE480252T1 (de) Peptidantagonist von zonulin und dessen verwendung
DE69333594D1 (de) Für menschliche alpha-1-adrenerge rezeptoren kodierende dns und ihre verwendung
WO1995013374A3 (en) Human and mouse very low density lipoprotein receptors and methods for use of such receptors
OA09704A (en) Antibody antagonist of human interleukin-4.
AU9135691A (en) G protein-coupled glutamate receptors
EA199900869A1 (ru) Цитокин-подобный фактор 7 млекопитающих
ATE299935T1 (de) Für polykationen sensitiver rezeptor von aquatischen lebewesen und methoden für seine verwendung.
DK1056449T3 (da) 20-HETE-antagonister og -agonister
NO953270L (no) Fibrinogenreceptorantagonister
ATE291615T1 (de) Testverfahren für agonisten und antagonisten des g protein gekoppelten rezeptors
Hoegen et al. Internalization of interleukin 1 (IL 1) correlates with IL 1‐induced IL 2 receptor expression and IL 2 secretion of EL4 thymoma cells
Miyazaki et al. LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice
ATE371730T1 (de) Detektionsverfahren umfassend die verwendung von polypeptiden mit einem coiled-coil und einer additionsstelle
ES8800722A1 (es) Metodo de produccion de un factor liberador de la hormona del crecimiento por la expresion en e. coli de polipeptidos hibridos
NO960715D0 (no) Fremgangsmåter for sceening av anti-östrogen forbindelser
Diamond et al. Lineage-specific expression of a T cell receptor variable gene promoter controlled by upstream sequences.
ATE294861T1 (de) Polypeptide mit opioider rezeptor-aktvität, für sie kodierende nukleinsäuren und ihre verwendungen
ITMI922854A0 (it) Nuovo uso degli antagonisti dei recettori 5-ht3
SE9700566D0 (sv) Modified proteins
DK1016714T3 (da) Nyt plasmid DNA indeholdende reportergen DNA og anvendelse af samme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties